Drugs & Aging

, Volume 26, Supplement 1, pp 75–87 | Cite as

Pharmacoeconomics and Aging

  • Silvia Bustacchini
  • Andrea Corsonello
  • Graziano Onder
  • Enrico Eugenio Guffanti
  • Flavio Marchegiani
  • Angela Marie Abbatecola
  • Fabrizia Lattanzio
Review Article


The aging of the general population in industrialized countries has brought to public attention the increasing incidence of age-related clinical conditions, because the long-term impact of diseases on functional status and on costs are greater in older people than in any other age group. With the aging of the population, it is becoming increasingly important to quantify the burden of illness in the elderly; this will be vital not only in planning for the necessary health services that will be required in coming years, but also in order to measure the benefit to be expected from interventions to prevent disability in older people. The management of multiple and chronic disorders has become a more important issue for healthcare authorities because of increasing requests for medical assistance and healthcare interventions. Among these, pharmacological treatments and drug utilization in older people are pressing issues for healthcare managers and politicians; indeed, a relatively small proportion of the population accounts for a substantial part of public drug costs. Two key sources of pressure are well known: the growing number of elderly persons, who are the highest per-capita users of medicines, and the introduction of new, often more expensive, medicines. On the other hand, the development of strategies for controlling costs, while providing the elderly with equitable access to needed pharmaceuticals, should be based on an evaluation of the economic impact of pharmacological care in older people, taking into account the burden of illness, drug utilization data, drug technology assessment evidence and results. Furthermore, there are major factors affecting pharmacological care in older people: for example inappropriate prescribing, lack of adherence and compliance, and the burden of adverse drug events. The assessment of these factors should be considered a priority in pharmacoeconomic evaluations in the aging population, and the most relevant evidence will be reviewed in this paper with examples referring to particular settings or conditions and diseases, such as the presence of cardiovascular risk factors, diabetes and chronic pain.



No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Eurostat, Statistics in Focus, 72/2008 “Ageing characterises the demographic perspectives of the European societies”. Available from the Eurostat Web site at URL: http://epp.eurostat.ec.europa.eu/cache/ITY_OFFPUB/KS-SF-08-072/EN/KS-SF-08-072-EN.PDF [Accessed 2009 Aug 3]
  2. 2.
    Wiener JM, Tilly J. Population ageing in the United States of America: implications for public programmes. Int J Epidemiol 2002; 31: 776–81PubMedCrossRefGoogle Scholar
  3. 3.
    Fifty facts from The World Health Report 1998 Global health situation and trends 1955–2025. WHO 1998. Available from the WHO Web site at URL: http://www.who.int/whr/1998/media_centre/50facts/en/index.html [Accessed 2009 Aug 3]
  4. 4.
    OECD. Projecting OECD Health and Long-Term Care Expenditures: What Are the Main Drivers? Economics Department Working Papers, No. 477 OECD Publishing, 2006. Available through OECD’s Web site at URL: http://www.oecd.org/dataoecd/57/7/36085940.pdf [Accessed 2009 Aug 3]CrossRefGoogle Scholar
  5. 5.
    Dormont B, Grignon M, Huber H. Health expenditure growth: reassessing the threat of ageing. Health Econ 2006; 15: 947–63PubMedCrossRefGoogle Scholar
  6. 6.
    Fernandez-Olano C, Hidalgo JD, Cerda-Diaz R, et al. Factors associated with health care utilization by the elderly in a public health care system. Health Policy 2006; 75: 131–9PubMedCrossRefGoogle Scholar
  7. 7.
    Saver BG, Doescher MP, Jackson JE, et al. Seniors with chronic health conditions and prescription drugs: benefits, wealth, and health. Value Health 2004; 7: 133–43PubMedCrossRefGoogle Scholar
  8. 8.
    Williams A. An aging population — burden or blessing? Value Health 2005; 8: 447–50PubMedCrossRefGoogle Scholar
  9. 9.
    OECD Health Data 2009-Frequently Requested Data. OECD 2009. Available through OECD’s Web site at URL: http://www.oecd.org/document/16/0,3343,en_2649_34631_2085200_1_1_1_1,00.html [Accessed 2009 Aug 3]
  10. 10.
    Health at a glance 2007: OECD indicators. OECD 2007. Available through OECD’s Web site at URL: http://www.healthinsite.gov.au/news/Health_at_a_Glance_2007_OECD_Indicators [Accessed 2009 Aug 3]
  11. 11.
    Clemente J, Marcuello C, Montanes A. Pharmaceutical expenditure, total health-care expenditure and GDP. Health Economics 2008; 17: 1187–206PubMedCrossRefGoogle Scholar
  12. 12.
    van Mosseveld C. Pharmaceutical expenditure compared across countries. Can J Clin Pharmacol 2005 Fall; 12(3): e269–75PubMedGoogle Scholar
  13. 13.
    Austvoll-Dahlgren A, Aaserud M, Vist G, et al. Pharmaceutical policies: effects of cap and co-payment on rational drug use. Cochrane Database Syst Rev 2008 Jan 23Google Scholar
  14. 14.
    Lambrelli D, O’Donnell O. Health, Econometrics and Data Group (HEDG) Working Paper 09/06. Why Does the Utilization of Pharmaceuticals Vary So Much Across Europe? Evidence from Micro Data on Older Europeans 2009. Available at URL: http://www.york.ac.uk/res/herc/documents/wp/09_06.pdf [Accessed 2009 Aug 3]
  15. 15.
    OECD Health Policy Studies. Pharmaceutical Pricing Policies in a Global Market. Paris, France: OECD, 2008Google Scholar
  16. 16.
    Freund DA, Willison D, Reeher G, et al. Outpatient pharmaceuticals and the elderly: policies in seven nations. Health Aff (Millwood) 2000 May–Jun; 19(3): 259–66CrossRefGoogle Scholar
  17. 17.
    Cornelius C. Drug use in the elderly: risk or protection? Curr Opin Psychiatry 2004; 17(6): 443–8CrossRefGoogle Scholar
  18. 18.
    Al-Windi A, Elmfeldt D, Svardsudd K. The relationship between age, gender, well-being and symptoms, and the use of pharmaceuticals, herbal medicines and selfcare products in a Swedish municipality. Eur J Clin Pharmacol 2000; 56: 311–7PubMedCrossRefGoogle Scholar
  19. 19.
    Green CA, Pope CR. Gender, psychosocial factors and the use of medical services: a longitudinal analysis. Soc Sci Med 1999; 48: 1363–72PubMedCrossRefGoogle Scholar
  20. 20.
    Furu K, Straume B, Thelle DS. Legal drug use in a general population: association with gender, morbidity, health care utilization, and lifestyle characteristics. J Clin Epidemiol 1997; 50: 341–9PubMedCrossRefGoogle Scholar
  21. 21.
    Eggen AE. Pattern of drug use in a general populationprevalence and predicting factors: the Tromso study. Int J Epidemiol 1994; 23: 1262–72PubMedCrossRefGoogle Scholar
  22. 22.
    Healthy Ageing: a Challenge for Europe. Report from the Healthy Ageing Project. 2007. Available from the “Healthy Ageing” Project Web site at URL: http://www.healthyageing.nu/upload/Rome/Healthy_web.pdf [Accessed 2009 Aug 3]
  23. 23.
    O’Neill C, Hughes CM, Jamison J, et al. Cost of pharmacological care of the elderly: implications for healthcare resources. Drugs Aging 2003; 20(4): 253–61PubMedCrossRefGoogle Scholar
  24. 24.
    EURO-MED-STAT — The Library of European Union Pharmaceutical Indicators: Expenditure and Utilisation Indicators. Final version. March 2004. Available from the “EuroMedStat” Project Web site at URL: http://www.euromedstat.cnr.it/pdf/EURO-MED-STAT3_utilisation.pdf [Accessed 2009 Aug 3]
  25. 25.
    Working Group of The National Drug Utilisation Monitoring Centre (OsMed). Drug utilization in Italy. National report. Year 2008. Il Pensiero Scientifico Editore, 2009 [in Italian] [Gruppo di lavoro OsMed. L’uso dei farmaci in Italia. Rapporto nazionale anno 2008. Roma: Il Pensiero Scientifico Editore, 2009.] Available at URL: http://www.agenziafarmaco.it/allegati/rapporto_osmed_2008.pdf. [Accessed 2009 Aug 3]Google Scholar
  26. 26.
    Lernfelt B, Samuelsson O, Skoog I, et al. Changes in drug treatment in the elderly between 1971 and 2000. Eur J Clin Pharmacol 2003 Nov; 59(8–9): 637–44PubMedCrossRefGoogle Scholar
  27. 27.
    The NHS Information Centre, Prescribing Support Unit Prescriptions dispensed in the community, statistics for 1998 to 2008: England. The Health and Social Care Information Centre, Prescribing Support Unit; 2009. Available at URL: http://www.ic.nhs.uk/statistics-and-data-collections/primarycare/prescriptions/prescriptions-dispensed-in-the-communitystatistics-for-1998-to-2008:-england [Accessed 2009 Aug 3]Google Scholar
  28. 28.
    CMS. Centers for Medicare and Medicaid Services. NHE Fact Sheet. Health expenditures by age. Selected Years 1987, 1996, 1999, 2002, and 2004. Available at URL: http://www.cms.hhs.gov/NationalHealthExpendData/downloads/2004-age-tables.pdf [Accessed 2009 Aug 3]
  29. 29.
    Kobayashi Y. Health care expenditures for the elderly and reforms in the health care system in Japan. Health Policy 1994; 29: 197–208PubMedCrossRefGoogle Scholar
  30. 30.
    Reinhardt UE, Hussey PS, Anderson GF. Cross-national comparisons of health systems using OECD data, 1999. Health Affairs 2002 May/June; 21(3): 169–81PubMedCrossRefGoogle Scholar
  31. 31.
    Bodenheimer TS. Affordable prescriptions for the elderly. JAMA 2001; 286: 1762–3PubMedCrossRefGoogle Scholar
  32. 32.
    Heinrich S, Luppa M, Matschinger H, et al. Service utilization and health-care costs in the advanced elderly. Value Health 2008 Jul–Aug; 11(4): 611–20PubMedCrossRefGoogle Scholar
  33. 33.
    Mueller C, Schur C, O’Connell J. Prescription drug spending: the impact of age and chronic disease status. Am J Public Health 1997; 87(10): 1626–9PubMedCrossRefGoogle Scholar
  34. 34.
    Hoffman C, Rice D, Sung HY. Persons with chronic conditions. Their prevalence and costs. JAMA 1996 Nov 13; 276(18): 1473–9PubMedCrossRefGoogle Scholar
  35. 35.
    Liu L, Cline RR, Schondelmeyer SW, et al. Pharmaceutical expenditures as a correlate of population health in industrialized nations. Ann Pharmacother 2008 Mar; 42(3): 368–74PubMedCrossRefGoogle Scholar
  36. 36.
    Crémieux PY, Ouellette P, Petit P. Do drugs reduce utilisation of other healthcare resources? Pharmacoeconomics 2007; 25(3): 209–21PubMedCrossRefGoogle Scholar
  37. 37.
    Lubitz J, Cai L, Kramarow E, et al. Health, life expectancy, and health care spending among the elderly. N Engl J Med 2003 Sept 11; 349(11): 1048–55PubMedCrossRefGoogle Scholar
  38. 38.
    Miller Jr RD, Frech HE. Is there a link between pharmaceutical consumption and improved health in OECD countries? Pharmacoeconomics 2000; 18Suppl. 1: 33–45CrossRefGoogle Scholar
  39. 39.
    Baker D, Fugh-Berman A. Do new drugs increase life expectancy? A critique of a Manhattan institute paper. J Gen Intern Med 2009 May; 24(5): 678–82PubMedCrossRefGoogle Scholar
  40. 40.
    Grootendorst P, Piérard E, Shim M. Life-expectancy gains from pharmaceutical drugs: a critical appraisal of the literature. Expert Rev Pharmacoecon Outcomes Res 2009 Aug; 9(4): 353–64PubMedCrossRefGoogle Scholar
  41. 41.
    Fialová D, Topinková E, Gambassi G, et al., AdHOC Project Research Group. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA 2005; 293: 1348–58PubMedCrossRefGoogle Scholar
  42. 42.
    Jackson S, Jansen P, Mangoni A, editors. Prescribing for Elderly Patients. Chichester, UK: John Wiley & Sons, 2009Google Scholar
  43. 43.
    OECD Health Working Papers No. 42. Policies for Healthy Ageing: An Overview. OECD 2009. Available through OECD’s Web site at URL: http://www.olis.oecd.org/olis/2009doc.nsf/LinkTo/NT00000BDE/$FILE/JT03259727.PDF [Accessed 2009 Aug 3]
  44. 44.
    Johnell K, Fastbom J, Rosen M, et al. Inappropriate drug use in the elderly: a nationwide register-based study. Ann Pharmacother 2007; 41(7): 1243–8PubMedCrossRefGoogle Scholar
  45. 45.
    Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf 2007; 30(10): 911–8PubMedCrossRefGoogle Scholar
  46. 46.
    Fialová D, Onder G. Medication errors in elderly people: contributing factors and future perspectives. Br J Clin Pharmacol 2009; 67: 641–5PubMedCrossRefGoogle Scholar
  47. 47.
    Cadieux RJ. Drug interactions in the elderly. How multiple drug use increases risk exponentially. Postgrad Med 1989; 86(8): 179–86PubMedGoogle Scholar
  48. 48.
    Johnssons JA, Bootman JL. Drug-related morbidity and mortality. Arch Intern Med 1995; 155: 1949–56CrossRefGoogle Scholar
  49. 49.
    Hanlon JT, Schmader KE, Ruby CM, et al. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc 2001; 49: 200–9PubMedCrossRefGoogle Scholar
  50. 50.
    Liu GG, Christensen DB. The continuing challenge of inappropriate prescribing in the elderly: an update of the evidence. J Am Pharm Assoc 2002; 42(6): 847–57CrossRefGoogle Scholar
  51. 51.
    Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash) 2001; 41(2): 192–9Google Scholar
  52. 52.
    Mjorndal T, Boman MD, Hagg S, et al. Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiol Drug Saf 2002; 11(1): 65–72PubMedCrossRefGoogle Scholar
  53. 53.
    Bero LA, Lipton HL, Bird JA. Characterization of geriatric drug-related hospital readmissions. Med Care 1991; 29: 989–1003PubMedCrossRefGoogle Scholar
  54. 54.
    Bootman JL, Harrison DL, Cox E. The health care cost of drug-related morbidity and mortality in nursing facilities. Arch Intern Med 1997; 157: 2089–96PubMedCrossRefGoogle Scholar
  55. 55.
    Burton MM, Hope C, Murray MD, et al. The cost of adverse drug events in ambulatory care. AMIA Annu Symp Proc 2007; 11: 90–3Google Scholar
  56. 56.
    Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 1997 Jan 22–29; 277(4): 307–11PubMedCrossRefGoogle Scholar
  57. 57.
    Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997 Jan 22–29; 277(4): 301–6PubMedCrossRefGoogle Scholar
  58. 58.
    Fick DM, Mion LC, Beers MH, et al. Health outcomes associated with potentially inappropriate medication use in older adults. Res Nurs Health 2008 Feb; 31(1): 42–51PubMedCrossRefGoogle Scholar
  59. 59.
    Horne R, Weinman J, Barber N, et al. Concordance, adherence and compliance in medicine taking: Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R & D (NCCSDO). London, 2005. Available at URL: http://www.medslearning.leeds.ac.uk/pages/documents/useful_docs/76-final-report%5B1%5D.pdf [Accessed 2009 Aug 3]Google Scholar
  60. 60.
    Cramer JA. Enhancing patient compliance in the elderly. Role of packaging aids and monitoring. Drugs Aging 1998; 12(1): 7–15PubMedCrossRefGoogle Scholar
  61. 61.
    Kusserow RP. Medication Regimens: Causes of Non-compliance. Washington, DC: Office of Inspector General, U.S. Department of Health and Human Services, 1990: WOEI-04-89-8912Google Scholar
  62. 62.
    Sullivan SD, Kreling DH, Hazlet TK. Noncompliance with medication regimens and subsequent hospitalizations: a literature analysis and cost of hospitalization estimate. J Res Pharm Econ 1990; 2: 19–33Google Scholar
  63. 63.
    Hughes DA, Bagust A, Haycox A, et al. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 2001; 10: 601–15PubMedCrossRefGoogle Scholar
  64. 64.
    Hughes DA, Bagust A, Haycox A, et al. Accounting for noncompliance in pharmacoeconomic evaluations. Pharmacoeconomics 2001; 19(12): 1185–97PubMedCrossRefGoogle Scholar
  65. 65.
    Lindley CM, Tully MP, Paramsothy V, et al. Inappropriate medication is a major cause of adverse drug reactions in elderly patients. Age Ageing 1992; 21: 294–300PubMedCrossRefGoogle Scholar
  66. 66.
    Bates DW, Boyle DL, VanderVliet MB, et al. Relationship between medication errors and adverse drug events. J Gen Intern Med 1995; 10: 199–205PubMedCrossRefGoogle Scholar
  67. 67.
    Swedish National Institute of Public Health (SNIPH) (2007), Healthy Ageing: a Challenge for Europe, Brussels [Stockholm], www.healthyageing.nu. Available at URL: http://www.fhi.se/PageFiles/4173/Healthy_ageing.pdf [Accessed 2009 Aug 3]Google Scholar
  68. 68.
    Institute of Medicine. Preventing Medication Errors. 2006. Available at URL: www.iom.edu/Object.File/Master/35/943/medication%20errors%20new.pdf [Accessed 2009 Aug 3]
  69. 69.
    Fillenbaum GG, Hanlon JT, Landerman LR, et al. Impact of inappropriate drug use on health services utilization among representative older community-dwelling residents. Am J Geriatr Pharmacother 2004 Jun; 2(2): 92–101PubMedCrossRefGoogle Scholar
  70. 70.
    Zermansky AG, Silcock J. Is medication review by primary-care pharmacists for older people cost effective?: a narrative review of the literature, focusing on costs and benefits. Pharmacoeconomics 2009; 27(1): 11–24PubMedCrossRefGoogle Scholar
  71. 71.
    Murray MD, Callahan CM. Improving medication use for older adults: an integrated research agenda. Ann Intern Med 2003 Sept 2; 139 (5 Pt 2): 425–9PubMedGoogle Scholar
  72. 72.
    Elliott WJ, Black HR. Treatment of hypertension in the elderly. Am J Geriatr Cardiol 2002 Jan–Feb; 11(1): 11–20PubMedCrossRefGoogle Scholar
  73. 73.
    Roberts RL, Small RE. Cost of treating hypertension in the elderly. Curr Hypertens Rep 2002 Dec; 4(6): 420–3PubMedCrossRefGoogle Scholar
  74. 74.
    Linjer E, Jörnmark J, Hedner T, et al., Stop Hypertension-2 Group. Predictors for high costs of hospital care in elderly hypertensive patients. Blood Press 2006; 15(4): 245–50PubMedCrossRefGoogle Scholar
  75. 75.
    Rashidi A, Wright JT. Drug treatment of hypertension in older hypertensives. Clin Geriatr Med 2009; 25: 235–44PubMedCrossRefGoogle Scholar
  76. 76.
    Wright Jr JT, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005; 293(13): 1595–608PubMedCrossRefGoogle Scholar
  77. 77.
    Primatesta P, Poulter NR. Hypertension management and control among English adults aged 65 years and older in 2000 and 2001. J Hypertens 2004; 22: 1093–8PubMedCrossRefGoogle Scholar
  78. 78.
    Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362(9395): 1527–35PubMedCrossRefGoogle Scholar
  79. 79.
    Dahlof B, Hansson L, Lindholm L, et al., Swedish Trial in Old Patients with Hypertension. A prospective multicentre study in Swedish primary health care. Scand J Prim Health Care 1986; 4: 165–8PubMedCrossRefGoogle Scholar
  80. 80.
    Group SCR. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265(24): 3255–64CrossRefGoogle Scholar
  81. 81.
    Rutan GH, Kuller LH, Neaton JD, et al. Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. Circulation 1988; 77(3): 504–14PubMedCrossRefGoogle Scholar
  82. 82.
    Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350(9080): 757–64PubMedCrossRefGoogle Scholar
  83. 83.
    Wang JG, Staessen JA, Gong L, et al. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 2000; 160(2): 211–20PubMedCrossRefGoogle Scholar
  84. 84.
    Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355(9207): 865–72PubMedCrossRefGoogle Scholar
  85. 85.
    Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358(18): 1887–98PubMedCrossRefGoogle Scholar
  86. 86.
    McMurray J. The health economics of the treatment of hyperlipidemia and hypertension. Am J Hypertens 1999; 12: 99S–104SPubMedCrossRefGoogle Scholar
  87. 87.
    Johannesson M, Dahlof B, Lindholm LH, et al. The cost-effectiveness of treating hypertension in elderly people— an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). J Intern Med 1993; 234: 317–23PubMedCrossRefGoogle Scholar
  88. 88.
    Hulley SB, Furberg CD, Gurland B, et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. Am J Cardiol 1985; 56: 913–20PubMedCrossRefGoogle Scholar
  89. 89.
    Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension. can better care cost less? JAMA 2004; 291: 1850–6PubMedCrossRefGoogle Scholar
  90. 90.
    Dunn EC, Small RE. Economics of antihypertensive therapy in the elderly. Drugs & Aging 2001; 18(7): 515–25CrossRefGoogle Scholar
  91. 91.
    Ducharme N, Radhamma R. Hyperlipidemia in the elderly. Clin Geriatr Med 2008; 24: 471–87PubMedCrossRefGoogle Scholar
  92. 92.
    Acharjee S, Welty FK. Atorvastatin and cardiovascular risk in the elderly — patient considerations. Clin Interv Aging 2008; 3(2): 299–314PubMedGoogle Scholar
  93. 93.
    Mungall M, Gaw A, Shephard J. Statin therapy in the elderly. Does it make good clinical and economic sense? Drugs Aging 2003; 20(4): 263–75PubMedCrossRefGoogle Scholar
  94. 94.
    Ali R, Alexander KP. Statins for the primary prevention of cardiovascular events in older adults: a review of the evidence. Am J Geriatr Pharmacother 2007; 5: 52–63PubMedCrossRefGoogle Scholar
  95. 95.
    Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention in elderly patients. J Am Coll Cardiol 2008; 51: 37–45PubMedCrossRefGoogle Scholar
  96. 96.
    Tonkin AM, Eckermann S, White H, et al., LIPID Study Group. Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study. Am Heart J 2006 Jun; 151(6): 1305–12PubMedCrossRefGoogle Scholar
  97. 97.
    Mendelson G, Aronow WS. Underutilization of the measurement of serum low density lipoprotein cholesterol levels and of lipid lowering therapy in older patients who manifest arthersclerotic disease. J Gerontol 2002; 57: M398–400CrossRefGoogle Scholar
  98. 98.
    Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288(4): 462–7PubMedCrossRefGoogle Scholar
  99. 99.
    Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288(4): 455–61PubMedCrossRefGoogle Scholar
  100. 100.
    Diamond GA, Kaul S. Prevention and treatment: a tale of two strategies. J Am Coll Cardiol 2008; 51: 46–8PubMedCrossRefGoogle Scholar
  101. 101.
    Plosker GL, Figgitt DP. Repaglinide: a pharmacoeconomic review of its use in type 2 diabetes mellitus. Pharmacoeconomics 2004; 22(6): 389–411PubMedCrossRefGoogle Scholar
  102. 102.
    Massi-Benedetti M. CODE-2 Advisory Board. The cost of diabetes type II in Europe: the CODE-2 Study. Diabetologia 2002 Jul; 45(7): S1–4PubMedCrossRefGoogle Scholar
  103. 103.
    Jönsson B. CODE-2 Advisory Board. Revealing the cost of type II diabetes in Europe. Diabetologia 2002 Jul; 45(7): S5–12PubMedCrossRefGoogle Scholar
  104. 104.
    Lucioni C, Garancini MP, Massi-Benedetti M, et al. CODE-2 Italian Advisory Board. The costs of type 2 diabetes mellitus in Italy: a CODE-2 sub-study. Treat Endocrinol 2003; 2(2): 121–33PubMedCrossRefGoogle Scholar
  105. 105.
    Ober SK, Watts S, Lawrence RH. Insulin use in elderly diabetic patients. Clin Interv Aging 2006; 1(2): 107–13PubMedCrossRefGoogle Scholar
  106. 106.
    Oiknine R, Mooradian AD. Drug therapy of diabetes in the elderly. Biomed Pharmacother 2003 Jul–Aug; 57(5–6): 231–9PubMedCrossRefGoogle Scholar
  107. 107.
    Schwarz B, Gouveia M, Chen J, et al. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metab 2008 Jun; 10Suppl. 1: 43–55PubMedCrossRefGoogle Scholar
  108. 108.
    Miller DR, Gardner JA, Hendricks AM, et al. Health care resource utilization and expenditures associated with the use of insulin glargine. Clin Ther 2007 Mar; 29(3): 478–87PubMedCrossRefGoogle Scholar
  109. 109.
    Beale S, Bagust A, Shearer AT, et al. Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics 2006; 24Suppl. 1: 21–34PubMedGoogle Scholar
  110. 110.
    Palmer AJ, Roze S, Lammert M, et al. Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes. Curr Med Res Opin 2004 Aug; 20Suppl. 1: S41–51PubMedCrossRefGoogle Scholar
  111. 111.
    European Diabetes Working Party for Older People 2001–2004. Clinical Guidelines for Type 2 Diabetes Mellitus. Available at URL: http://www.instituteofdiabetes.org/wp-content/themes/IDOP/other/diabetes_guidelines_for_older_people.pdf [Accessed 2009 Aug 3]
  112. 112.
    McCarberg BH, Nicholson BD, Todd KH, et al. The impact of pain on quality of life and the unmet needs of pain management: results from pain sufferers and physicians participating in an Internet survey. Am J Ther 2008 Jul–Aug; 15(4): 312–20PubMedCrossRefGoogle Scholar
  113. 113.
    Gagliese L, Melzack R. Chronic pain in elderly people. Pain 1997 Mar; 70(1): 3–14PubMedCrossRefGoogle Scholar
  114. 114.
    Jensen MK, Thomsen AB, Højsted J. 10-Year follow-up of chronic non-malignant pain patients: opioid use, health related quality of life and health care utilization. Eur J Pain 2006 Jul; 10(5): 423–33PubMedCrossRefGoogle Scholar
  115. 115.
    Eriksen J, Sjøgren P, Ekholm O, et al. Health care utilisation among individuals reporting long-term pain: an epidemiological study based on Danish National Health Surveys. Eur J Pain 2004 Dec; 8(6): 517–23PubMedCrossRefGoogle Scholar
  116. 116.
    Garattini L, Koleva D, Motterlini N, et al. Medical costs of chronic musculoskeletal pain in Italy. Clin Drug Invest 2007; 27(2): 139–48CrossRefGoogle Scholar
  117. 117.
    Becker N, Sjøgren P, Bech P, et al. Treatment outcome of chronic non-malignant pain patients managed in a danish multidisciplinary pain centre compared to general practice: a randomised controlled trial. Pain 2000 Feb; 84(2–3): 203–11PubMedCrossRefGoogle Scholar
  118. 118.
    Thomsen AB, Sørensen J, Sjøgren P, et al. Chronic non-malignant pain patients and health economic consequences. Eur J Pain 2002; 6(5): 341–52PubMedCrossRefGoogle Scholar
  119. 119.
    Turk DC. Chronic non-malignant pain patients and health economic consequences. Eur J Pain 2002; 6(5): 353–5PubMedCrossRefGoogle Scholar
  120. 120.
    Underwood M, Ashby D, Carnes D, et al. Topical or oral ibuprofen for chronic knee pain in older people. The TOIB study. Health Technol Assess 2008 May; 12(22): iii–iv, ix–155PubMedGoogle Scholar
  121. 121.
    Pergolizzi J, Böger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008 Jul–Aug; 8(4): 287–313PubMedCrossRefGoogle Scholar
  122. 122.
    Vadivelu N, Hines RL. Management of chronic pain in the elderly: focus on transdermal buprenorphine. Clin Interv Aging 2008; 3(3): 421–30PubMedGoogle Scholar
  123. 123.
    Nikles CJ, Yelland M, Del Mar C, et al. The role of paracetamol in chronic pain: an evidence-based approach. Am J Ther 2005 Jan–Feb; 12(1): 80–91PubMedCrossRefGoogle Scholar
  124. 124.
    Klotz U. The elderly — a challenge for appropriate drug treatment. Eur J Clin Pharmacol 2008 Mar; 64(3): 225–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Silvia Bustacchini
    • 1
  • Andrea Corsonello
    • 2
  • Graziano Onder
    • 3
  • Enrico Eugenio Guffanti
    • 4
  • Flavio Marchegiani
    • 1
  • Angela Marie Abbatecola
    • 1
  • Fabrizia Lattanzio
    • 1
  1. 1.Scientific Direction, Italian National Research Centre on Aging (INRCA)AnconaItaly
  2. 2.Unit of Geriatric Pharmacoepidemiology, Research Hospital of CosenzaItalian National Research Centre on Aging (INRCA)CosenzaItaly
  3. 3.Centro Medicina dell’InvecchiamentoUniversità Cattolica del Sacro CuoreRomeItaly
  4. 4.Unit of Pulmonary Rehabilitation, Research Hospital of CasatenovoItalian National Research Centre on Aging (INRCA)CasatenovoItaly

Personalised recommendations